SCHEMBL24997802

SCHEMBL24997802

CC(C)NC(=O)C1CCCCCC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
LMNA P02545 2/20 0.51
HPGD P15428 2/20 0.51
TSHR P16473 2/20 0.51
POLB P06746 1/20 0.51
CHRNB2 P17787 1/20 0.50
CHRNB4 P30926 1/20 0.50
CHRNA3 P32297 1/20 0.50
CHRNA7 P36544 1/20 0.50
CHRNA4 P43681 1/20 0.50
RECQL P46063 1/20 0.50
GAA P10253 1/20 0.47
EPHX1 P07099 1/20 0.47
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL104815 1.00 SMN1; SMN2 (0.56) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL18935418 1.00 SMN1; SMN2 (0.56) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL24997854 1.00 SMN1; SMN2 (0.56) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL18935499 1.00 SMN1; SMN2 (0.56) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL1940413 0.98 SMN1; SMN2 (0.55) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
Hydrochloric Acid SCHEMBL573477 0.98 SMN1; SMN2 (0.55) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL1703385 0.98 SMN1; SMN2 (0.58) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL12375164 0.93 SMN1; SMN2 (0.58) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL172134 0.90
SCHEMBL10076786 0.90 SMN1; SMN2 (0.60) SMN1; SMN2MEN1KMT2AHDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159446-A1 Methods and Compositions for Targeting Tregs using CCR8 Inhibitors NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) 2023-05-25 US disclosed
US-20230159446-A1 Methods and Compositions for Targeting Tregs using CCR8 Inhibitors NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) 2023-05-25 US disclosed
US-20230038589-A1 Methods and compositions for targeting Tregs using CCR8 inhibitors Nanjing Immunophage Biotech Co., Ltd. (CN) 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159446-A1 Methods and Compositions for Targeting Tregs using CCR8 Inhibitors CCR8, CCR1, CCR3 SMN1; SMN2 4731/4885MEN1 3702/4885KMT2A 2533/4885
US-20230038589-A1 Methods and compositions for targeting Tregs using CCR8 inhibitors CCR8, CCR1, CCR3 SMN1; SMN2 4731/4885MEN1 3702/4885KMT2A 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.